A5034654609- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Cancer Genomics and Diagnostics
- Eosinophilic Disorders and Syndromes
- Chronic Myeloid Leukemia Treatments
- Lymphoma Diagnosis and Treatment
- Cancer-related molecular mechanisms research
- T-cell and Retrovirus Studies
- Kruppel-like factors research
- Circular RNAs in diseases
- Bone Metabolism and Diseases
- RNA modifications and cancer
- Genomics and Chromatin Dynamics
- DNA Repair Mechanisms
- BRCA gene mutations in cancer
- Cancer-related gene regulation
- Bone health and treatments
- Signaling Pathways in Disease
- Epigenetics and DNA Methylation
- Cytokine Signaling Pathways and Interactions
- Single-cell and spatial transcriptomics
- NF-κB Signaling Pathways
- Multiple Myeloma Research and Treatments
- Pancreatic and Hepatic Oncology Research
Azienda Sanitaria Unità Locale di Reggio Emilia
2023-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2023-2025
University of Modena and Reggio Emilia
2020-2022
Ferrari (Italy)
2020-2021
MRC Centre for Regenerative Medicine
2021
Institute for Biomedical Research and Innovation
2020
Istituto di Biomedicina e di Immunologia Molecolare Alberto Monroy
2019
National Research Council
2019
Abstract Chromatin modifiers are emerging as major determinants of many types cancers, including Anaplastic Large Cell Lymphomas (ALCL), a family highly heterogeneous T-cell lymphomas for which therapeutic options still limited. HELLS is multifunctional chromatin remodeling protein that affects genomic instability by participating in the DNA damage response. Although transcriptional function has been suggested, no clues on how controls transcription currently available. In this study,...
Myelofibrosis (MF) is the Philadelphia-negative myeloproliferative neoplasm characterized by worst prognosis and no response to conventional therapy. Driver mutations in JAK2 CALR impact on JAK-STAT pathway activation but also production of reactive oxygen species (ROS). ROS play a pivotal role inflammation-induced oxidative damage cellular components including DNA, therefore leading greater genomic instability promoting cell transformation. In order unveil driver stress, we assessed levels...
Long non-coding RNAs (lncRNAs) have been recently described as key mediators in the development of hematological malignancies. In last years, circulating lncRNAs proposed a new class non-invasive biomarkers for cancer diagnosis and prognosis to predict treatment response. The present study is aimed investigate potential prognostic myelofibrosis (MF), most severe among Philadelphia-negative myeloproliferative neoplasms. We detected increased levels seven plasma samples MF patients (n = 143),...
Disease progression of myeloproliferative neoplasms is the result increased genomic complexity. Since ability to predict disease evolution crucial for clinical decisions, we studied single-cell genomics and transcriptomics CD34-positive cells from a primary myelofibrosis (PMF) patient who progressed acute myeloid leukemia (AML) while receiving Ruxolitinib. Single-cell allowed reconstruction clonal hierarchy demonstrated that TET2 was first mutated gene FLT3 last one. accompanied by...
NFATc1, which is ubiquitous in many cell types, the master regulator of osteoclastogenesis. However, molecular mechanisms by NFATc1 drives its transcriptional program to produce osteoclasts from macrophages (M) remains poorly understood. We performed quantitative PCR (QPCR) arrays and bioinformatic analyses discover new direct indirect targets. The results revealed that significantly modified expression 55 genes untransfected cells 31 after NFATc1-knockdown (≥2). Among them, we focused on 19...
Abstract Myelofibrosis (MF) belongs to the family of classic Philadelphia-negative myeloproliferative neoplasms (MPNs). It can be primary myelofibrosis (PMF) or secondary (SMF) evolving from polycythemia vera (PV) essential thrombocythemia (ET). Despite differences, PMF and SMF patients are currently managed in same way, prediction survival is based on clinical genetic features. In last few years, interest has grown concerning ability gene expression profiles (GEPs) provide valuable...
Macrophages are mononuclear cells that become osteoclasts (OCs) in the presence of two cytokines, macrophage colony-stimulating factor (M-CSF), and receptor activator NF-κB ligand (RANKL). RANKL binding to its specific RANK leads OCs differentiation mainly by nuclear activated T-cells cytoplasmic 1 (NFATc1). In our previous study, analysis protein network NFATc1-knockdown cells, using Ingenuity Pathway Analysis (IPA), showed a link between NFATc1 Mitogen-activated kinase (MEK)-extracellular...
Next-generation sequencing (NGS)-based cancer risk screening with multigene panels has become the most successful method for programming prevention strategies. ATM germ-line heterozygosity been described to increase tumor susceptibility. In particular, families carrying heterozygous variants of gene have a 5- 9-fold developing breast cancer. Recent studies identified as second mutated after CHEK2 in BRCA-negative patients. Nowadays, more than 170 missense and several truncating mutations...
Single-cell genomics has become the method of choice for study heterogeneous cell populations and represents an elective application in defining architecture clonal evolution hematological neoplasms. Reconstructing a neoplastic population therefore main way to understand more deeply pathogenesis neoplasm, but it is also potential tool tumor with respect its response therapy. Pre-analytical phase single-cell analysis crucial obtain suitable sorting, whole genome amplification required...
Next Generation Sequencing based cancer risk screening with multigene panels has become the most successful method for programming prevention strategies. ATM germ-line heterozygosity been described as able to increase tumor susceptibility. In particular, families that carry heterozygous variants of gene show a 5- 9-fold developing breast cancer. Recent studies identified second mutated after CHEK2 in BRCA-negative patients. Nowadays, more than 170 potential missense and several truncating...
Background: Primary myelofibrosis (PMF) together with polycythemia vera (PV) and essential thrombocythemia (ET) belongs to the classic Philadelphia-negative myeloproliferative neoplasms (MPNs). PV ET can evolve secondary (SMF) giving rise post-PV (PPV) post-ET (PET) (MF). PMF SMF patients are currently managed in same way prediction of survival is based on prognostic models, even if it has been demonstrated that they can’t accurately distinguish different risk categories SMF. In last few...
Disease progression of myeloproliferative neoplasms is the result increased genomic complexity. Since ability to predict disease evolution crucial for clinical decision, we studied single cell genomics and transcriptomics CD34+ cells from a primary myelofibrosis (PMF) patient who progressed acute myeloid Leukemia (AML) while receiving Ruxolitinib. Single allowed reconstruction clonal hierarchy demonstrated that TET2 was first mutated gene FLT3 last one. accompanied by heterogeneity...
Background: Primary myelofibrosis (PMF) is a stem cell disorder belonging to Philadelphia-negative myeloproliferative neoplasms (MPNs). The disruption of bone marrow (BM) microenvironment due the extensive deposition extracellular matrix fibers distinctive trait PMF and accompanied by hematopoietic cells (HSCs) mobilization extramedullary hematopoiesis. BM fibrosis caused complex interaction between stromal neoplastic clone, in particular megakaryocytes monocytes play pivotal role through...
Background: Myeloproliferative neoplasms (MPNs) are a group of hematopoietic stem cell disorders resulting in the overproduction myeloid differentiated cells. Primary Myelofibrosis (PMF) is characterized by worst prognosis and 15-20% cases develop secondary Acute Myeloid Leukemia (AML). MPNs driver mutations affect JAK2, CALR or MPL genes. Moreover, epigenetic regulators can exacerbate disease alter response to treatment. Our recently demonstrated through single analysis that progression due...
Background: Myelofibrosis (MF) is the Philadelphia-negative myeloproliferative neoplasm characterized by worst prognosis and poor response to conventional therapy. Driver mutations in JAK2 CALR impact on JAK-STAT pathway activation but also production of reactive oxygen species (ROS). ROS play a pivotal role inflammation-induced oxidative damage cellular components including DNA, that leads greater genomic instability promotes cell transformation. Aims: In order unveil driver stress...
Background: Myelofibrosis (MF) displays the worst prognosis among Philadelphia-negative myeloproliferative neoplasms and is characterized by megakaryocyte hyperplasia, progressive bone marrow fibrosis, extramedullary hematopoiesis frequent transformation to acute myeloid leukemia. Different therapeutic approaches are being used depending on severity specific clinical manifestations of disease in each patient. Unfortunately, no curative therapy currently available for MF, except...